A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis

Keyphrases

• Myelofibrosis 100%
• Ruxolitinib 100%
• Phase I Trial 100%
• Pevonedistat 100%
• Combination Therapy 66%
• Myeloproliferative Neoplasms 66%
• Inflammatory Cytokines 33%
• Adverse Events 33%
• Anemia 33%
• Interleukin-6 33%
• Oncogenic Pathways 33%
• Dose-limiting Toxicity 33%
• Dose Effect 33%
• Durable Response 33%
• Treatment Efficacy 33%
• Interferon-γ 33%
• Tolerability 33%
• Nuclear factor-κB 33%
• Single-agent Therapy 33%
• Janus Kinase 2 (JAK2) 33%
• Standard-of-care Therapy 33%
• Janus Kinase Inhibitors 33%
• Treatment Alteration 33%
• Phase I Dose-escalation Trials 33%
• Iron Parameters 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Combination Therapy 100%
• Myelofibrosis 100%
• Ruxolitinib 100%
• Phase I Trials 100%
• Pevonedistat 100%
• Myeloproliferative Neoplasm 66%
• Anemia 33%
• Adverse Event 33%
• Biological Marker 33%
• Cytokine 33%
• Nuclear Factor 33%
• Interleukin 6 33%
• Tolerability 33%
• Gamma Interferon 33%
• Iron 33%
• Janus Kinase 2 33%
• Janus Kinase 2 Inhibitor 33%